Clinical trial NCT02531178: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis
Official title: A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2015-08-24
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate. ABBV-257 or placebo will be administered once every other week (EOW) for a total of 4 doses. Subjects will continue on their stable dose of methotrexate weekly throughout participation in the study.

This study will be conducted in approximately 24 subjects in 3 dose groups, with 8 subjects per group. Within each group, 6 subjects will be randomized to receive ABBV-257 and 2 subjects will receive placebo. Subjects participating in one dose group will be ineligible to participate in another dose group in the study.

Detailed description: Multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Rheumatoid Arthritis based on the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria, or ACR 1987 for patients with diagnosis prior 2011 ≥ 3 months.
* Except for methotrexate (MTX), the subject must have discontinued all disease modifying anti-rheumatic drugs (DMARD) for at least 5 half-lives before the first dose of study drug, and undergone cholestyramine washout if received Leflunomide within the past 3 months.
* Subject must have been on MTX therapy \> 3 months and on a stable dose (7.5 - 25 mg/week), for at least 4 weeks prior to the first dose of study drug. Subject must be able to continue on stable dose of MTX for the duration of study participation.
* Body Mass Index (BMI) is 19 to 35, inclusive. (BMI is calculated as weight \[kg\] divided by height \[m2\].)
* Judged to be in good general health as determined by the Investigator based upon the results of medical history, laboratory profile, physical examination and 12-lead electrocardiogram (ECG) performed at screening

Exclusion Criteria:

* Evidence of anti-ABBV-257 antibody results in a pre-study serum sample.
* History of significant allergic reaction or significant sensitivity to any constituents of the study drug; or history of anaphylactic reaction to any agent (e.g., food products and bee sting); or history of a major reaction to any Immunoglobulin G (IgG) containing product.
* History of persistent chronic or active infection(s) requiring hospitalization or treatment with intravenous or oral antimicrobials/antibiotics within 30 days prior to initial study drug administration.
* History or evidence of active tuberculosis (TB) or the subject has evidence of risk factor for latent TB.
* Clinically significant abnormal screening laboratory results as evaluated by the Investigator, including serum values of Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) greater than 2.25 × the upper limit of normal, or creatinine greater than 1.5 × the upper limit of normal, or absolute neutrophil count \< 1500 μ/L.
* Subject has any medical condition or illness other than RA that is not well controlled with treatment that would, in the opinion of the investigator, preclude study participation or interfere with other symptoms of Rheumatoid Arthritis (RA).

Primary outcomes:
measure: Proportion of subjects with adverse events
timeFrame: Up to day 193
measure: Change in Vital signs
timeFrame: From day 1 to day 193
measure: Change in Physical examination
timeFrame: From day 1 to day 193
measure: Changes in Electrocardiogram (ECG)
timeFrame: From day 1 to day 193
measure: Maximum observed serum concentration (Cmax)
timeFrame: Up to day 50
measure: Time to maximum observed serum concentration (Tmax)
timeFrame: Up to day 50
Secondary outcomes:
measure: Immunogenicity by measurement of Anti-drug antibody
timeFrame: Up to day 193
Other outcomes:
measure: American College of Rheumatology (ACR) 20 response rate
timeFrame: Up to day 193
measure: American College of Rheumatology (ACR) 50 response rate
timeFrame: Up to day 193
measure: American College of Rheumatology (ACR) 70 response rate
timeFrame: Up to day 193
measure: Change in Disease Activity Score 28
timeFrame: From day 1 to day 193
Locations:
city: Berlin
country: Germany
facility: Site Reference ID/Investigator# 139394
Study officials:
affiliation: AbbVie
name: Heikki Mansikka, PhD
role: STUDY_DIRECTOR
References: